Inhalable viromimetic polymer nanoparticle vaccine (iVPNVax) in a subcutaneous-prime/inhalation-boost vaccination schedule for eliciting durable mucosal and systemic immune protection

Key Points

• This research aims to evaluate an inhalable viromimetic nanoparticle vaccine for inducing immune responses.
• Conducted a randomized trial assessing a subcutaneous-prime/inhalation-boost vaccination schedule.
• Utilized inhalable polymer nanoparticle technology for vaccine delivery to the lungs.
• Achieved sustained antigen retention in the lungs leading to strong immune responses.
• Elicited both mucosal and systemic immunity effectively.